Category

• Business1
• Products1

Organizations

• Bausch + Lomb64
• Alcon, Inc.43
• Eyes On Eyecare43
• American Optometric Association34
• Harrow28
• Glaukos26
• Regeneron22
• Topcon Healthcare22
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• AMD2
• DME2
• Diabetic Retinopathy2
• Injections2
• Retina2
• Retinal Vein Occlusion (rvo)2
• Wet Amd2
• Eylea1
• Fda Approval1
• Acquisitions1

• Organizations: Samsung Bioepis ✕

Clear all

Business

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio

Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.

Products

FDA approves first interchangeable aflibercept biosimilars

Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.